Success Metrics

Active Trials
4(100%)

Phase Distribution

Ph phase_2
2
50%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Recruiting3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 22 (50.0%)

Trials by Status

active_not_recruiting125%
recruiting375%

Recent Activity

4 active trials
Showing 4 of 4
recruitingphase_2

CD8 PET Imaging in Metastatic Solid Tumours

NCT06534190
recruitingphase_1

Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

NCT06650163
recruitingphase_1

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

NCT06863233
active_not_recruitingphase_2

Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

NCT05013099

Clinical Trials (4)

Showing 4 of 4 trials
NCT06534190Phase 2

CD8 PET Imaging in Metastatic Solid Tumours

Recruiting
NCT06650163Phase 1

Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

Recruiting
NCT06863233Phase 1

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

Recruiting
NCT05013099Phase 2

Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

Active Not Recruiting

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4